BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Company Registration Number:
14202804 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2025

Period of accounts

Start date: 1 January 2025

End date: 31 December 2025

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Directors' report period ended 31 December 2025

The directors present their report with the financial statements of the company for the period ended 31 December 2025

Principal activities of the company

BGO Europe IV Life Science TopCo Limited the “Company” was formed as a private limited company to acquire and hold BGO Newton HoldCo Limited (the 'Investment'). The Company qualifies as a small company as defined in the Companies Act 2006 in respect of the financial period, and has applied the rules of the ‘Small Companies Regime’ in accordance with applicable sections of the Companies Act 2006.



Directors

The directors shown below have held office during the whole of the period from
1 January 2025 to 31 December 2025

Ian Christopher Jason Ford
Gareth James Purcell


Secretary Citco REIF Services UK Limited

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
3 August 2026

And signed on behalf of the board by:
Name: Ian Christopher Jason Ford
Status: Director

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Profit And Loss Account

for the Period Ended 31 December 2025

2025 2024


£

£
Administrative expenses: ( 26,533 ) ( 25,914 )
Operating profit(or loss): (26,533) (25,914)
Interest receivable and similar income: 1,395 1,641
Profit(or loss) before tax: (25,138) (24,273)
Profit(or loss) for the financial year: (25,138) (24,273)

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Balance sheet

As at 31 December 2025

Notes 2025 2024


£

£
Fixed assets
Investments: 3 125,001 125,001
Total fixed assets: 125,001 125,001
Current assets
Cash at bank and in hand: 44,922 69,793
Total current assets: 44,922 69,793
Creditors: amounts falling due within one year: 4 ( 6,877 ) ( 6,610 )
Net current assets (liabilities): 38,045 63,183
Total assets less current liabilities: 163,046 188,184
Total net assets (liabilities): 163,046 188,184
Capital and reserves
Called up share capital: 300 300
Share premium account: 249,701 249,701
Profit and loss account: (86,955 ) (61,817 )
Total Shareholders' funds: 163,046 188,184

The notes form part of these financial statements

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Balance sheet statements

For the year ending 31 December 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 3 August 2026
and signed on behalf of the board by:

Name: Ian Christopher Jason Ford
Status: Director

The notes form part of these financial statements

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Other accounting policies

    2.1. Basis of preparation The financial statements have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, ‘The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland’ (‘FRS 102’) and the Companies Act 2006. The financial statements are denominated in pounds sterling (£ or GBP). These financial statements have been prepared using the historical cost convention. 2.2. Summary of disclosure exemptions The Company has taken advantages of the following exemptions for small entities in preparing financial statements, as permitted by FRS 102: - the requirements of Section 7 Statement of Cash Flows; - the requirements of Section 33 Related Party Disclosures paragraph 33.1A The Company has taken advantage of the exemption available in Section 414B of the Companies Act 2006 not to prepare a Strategic Report. 2.3. Going concern For the year ended 31 December 2025, no events or conditions were identified that would rise significant doubt about the Company’s ability to continue as going concern. After assessment conclusion was made that there is reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The Company therefore continues to adopt the going concern basis in preparing its financial statements. 2.4. Interest income Interest income is recognised using the effective interest rate method. 2.5. Expenses Expenses are recognised as soon as there is a legal or constructive obligation committing the Company to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accrual basis. 2.6. Investments Investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversal of impairment losses are recognised immediately in the Profit and Loss Account and Other Comprehensive Income. A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. 2.7. Cash and cash equivalents Cash and cash equivalents include cash in hand, deposits held at call with banks, other short term highly liquid investments with original maturities of three months or less. 2.8. Trade payables Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities. Trade payables are recognised initially at fair value and subsequently measured at amortized cost using the effective interest method. 2.9. Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds. Dividends and other distributions to company’s shareholders are recognised as a liability in the financial statements in the period in which the dividends and other distributions are approved by the company’s shareholders. These amounts are recognised in the statement of changes in equity. 2.10. Foreign currency transactions and balances Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured. Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated. Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the income statement for the period.

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 0 0

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

3. Fixed assets investments note

The subsidiaries, over which the Company exercises control via ordinary shares held directly by the Company at the end of the year are: BGO Newton HoldCo Limited - 100%

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

4. Creditors: amounts falling due within one year note

2025 2024
£ £
Accruals and deferred income 6,877 6,610
Total 6,877 6,610

BGO EUROPE IV LIFE SCIENCE TOPCO LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

5. Loans to directors

The Directors did not receive any remuneration from the Company in the year and no contributions were made by the Company during the year ended 31 December 2025.